Clover Biopharmaceuticals, Ltd. (2197.HK)

Descripción

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis. The company is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, it provides consulting services and sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People's Republic of China.